Project Grant K08HL179473
Award Date
7/16/25
Completion Date
6/30/30
Dollars Obligated
$167K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,781 to Mogling Bio Inc. to develop a therapeutic regimen that can attenuate aging of human hematopoietic stem cells (HSCs). The central goal is to validate the use of the drug CASIN to restore CDC42-regulated polarity and rejuvenate aged human HSCs ex vivo. This research aims to benefit bone marrow HSC transplant patients...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $623,874 to uncover novel regulatory pathways and functions of the telomerase RNA component (TERC) in the hematopoietic system. The research aims to identify regulators of TERC decay and its direct functions outside of telomere length regulation, which could explain the disproportionate role of TERC mutations in bone marrow failure. The...
This Project Grant award of $735,085 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Case Western Reserve University to investigate modulating the Heat Shock Transcription Factor 1 (HSF1) as a means to transform detrimental age-related clonal hematopoiesis (CH) into a state favoring normal blood cell production while preventing CH progression. The research aims to understand how deleting HSF1 along with the CH-associated...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) provides $549,796 to Cedars-Sinai Medical Center to conduct research focused on understanding how mutations in the TET2 and IDH2 genes associated with acute myeloid leukemia (AML) can impact cardiac metabolism and lead to cardiomyopathy and heart failure. The key research objectives are to: 1) Examine alterations in heart oxidative metabolism in response to TET2 or...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,419,308 to the University of Pittsburgh to investigate the mechanisms linking persistent DNA damage to the upregulation of NLRP12 and the functional links between persistent DNA damage and NLRP12 in aging hematopoiesis. The award period is from Sep 17, 2024 to Aug 31, 2025. The research aims to elucidate a novel interplay between...
This $153,696.00 Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), supports research aimed at elucidating the developmental origins and functional characteristics of myeloid-biased hematopoietic stem cells (HSCs) that emerge during fetal development. The principal investigator at The Leland Stanford Junior University will utilize advanced techniques such as flow cytometry, immunofluorescence, transplantation, and...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,922 to the Albert Einstein College of Medicine to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis. The research will utilize zebrafish models and human induced pluripotent stem cells (iPSCs) to characterize changes in hematopoietic stem and progenitor cells, as well as differentiated progeny, under these...
This $677,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to gain a mechanistic understanding of erythroid progenitor (EP) self-renewal, both in vitro and in vivo. The primary goals are to: Test the hypothesis that the BMI1/RING1B chromatin modulators regulate human self-renewing erythroblast (SRE) self-renewal through epigenetic control of transcription and cholesterol homeostasis. Test the hypothesis that...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357.00 to support research on the bone marrow microenvironment and its role in regulating blood cell production. The research, to be conducted by the Children's Hospital Medical Center in Cincinnati, Ohio, aims to define the spatial organization and specialized vascular microenvironments within the bone marrow that recruit and...
This federal Project Grant award for $657,368.00, issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the mechanisms controlling microRNA (miRNA) processing and degradation pathways during hematopoietic development. The primary awardee, The Washington University, will utilize human pluripotent stem cell lines with mutations in miRNA deadenylases and exosome components to identify novel...